Evidence map›Paper›PMID 40975077›Full record

ArticleThe Lancet. Global health2025

Breast cancer overall survival, annual risks of death, and survival gap apportionment in sub-Saharan Africa (ABC-DO): 7-year follow-up of a prospective cohort study.

Tingting Mo, Maureen Joffe, Herbert Cubasch, Moses Galukande, Groesbeck Parham, Leeya Pinder, Annelle Zietsman, Benjamin O Anderson, Allen Naamala, Agnes Kaggwa and 19 more

Abstract read
In one paragraph

Article in The Lancet. Global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Tingting MoEnvironment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Maureen JoffeUniversity of Witwatersrand, Johannesburg, South Africa.
Herbert CubaschUniversity of the Witwatersrand and Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.
Moses GalukandeMakerere University, Kampala, Uganda.
Groesbeck ParhamUNC Zambia, Lusaka, Zambia.
Leeya PinderUNC Zambia, Lusaka, Zambia.
Annelle ZietsmanWindhoek Central Hospital, Windhoek, Namibia.
Benjamin O AndersonFred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.
Allen NaamalaUganda Cancer Institute, Kampala, Uganda.
Agnes KaggwaMakerere University, Kampala, Uganda.
Teopista NakazibweMakerere University, Kampala, Uganda.
Anne NteziryayoMakerere University, Kampala, Uganda.
Johanna PontacWindhoek Central Hospital, Windhoek, Namibia.
Shadrach Awa OffiahAbia State University Teaching Hospital, Aba, Nigeria.
Angelica AngelicaFederal Medical Centre, Owerri, Nigeria.
Chris Sule OyamienlenFederal Medical Centre, Owerri, Nigeria.
Esther EzeigboFederal Medical Centre, Owerri, Nigeria.
Kingsley IwuohaFederal Medical Centre, Owerri, Nigeria.
Wenlong Carl ChenUniversity of Witwatersrand, Johannesburg, South Africa.
Emily WalubitaUniversity Teaching Hospital, Lusaka, Zambia.
Mildred LusakaUniversity Teaching Hospital, Lusaka, Zambia.
Mary NyangasiWorld Health Organization, Geneva, Switzerland.
Shamsudeen MohammedDepartment of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, UK.
Clement T NarhFred N Binka School of Public Health, University of Health and Allied Sciences, Ghana.
Pauline BoucheronEnvironment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Milena FoersterEnvironment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Joachim SchüzEnvironment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
Isabel Dos-Santos-SilvaDepartment of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, UK.
Valerie McCormackEnvironment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France. Electronic address: mccormackv@iarc.who.int.

Funding

Novel predictors of survival among breast cancer patients with/without HIV in South AfricaR01CA250012 · NCI · WITS HEALTH CONSORTIUM (PTY), LTD · PI CUBASCH, HERBERT, EL-SADR, WAFAA M. · 2020 to 2024
$2.0M
African Breast Cancer - Disparities in Outcomes - Plus (ABC-DO Plus): Ghana mentoring supplementR01CA244559 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI DOS SANTOS SILVA, ISABEL, MCCORMACK, VALERIE · 2020 to 2023
$1.9M
HIV's Effects on Breast Cancer Treatment and Outcomes in South AfricaR01CA192627 · NCI · WITS HEALTH CONSORTIUM (PTY), LTD · PI JACOBSON, JUDITH S, JOFFE, MAUREEN · 2015 to 2019
$1.7M
NCI NIH HHS R01 CA192627NCI NIH HHS R01 CA244559NCI NIH HHS R01 CA250012World Health Organization 001
6 · The paper itself

Abstract

backgroundThere are few estimates of breast cancer survival and its determinants at 5 years and beyond in sub-Saharan Africa. We aimed to estimate survival up to 7 years, estimate annual mortality risk, and apportion survival gaps.

methodsThe African Breast Cancer-Disparities in Outcomes (ABC-DO) prospective cohort study was done at eight hospitals across five sub-Saharan African countries (Namibia, Nigeria, South Africa, Uganda, and Zambia). We prospectively recruited women (aged ≥18 years) who attended hospital with suspected breast cancer. Vital status was updated telephonically once every 3 months for 7 years. We collected detailed sociodemographic, clinical, and treatment data. The primary outcome was overall survival. We estimated age-standardised net survival, conditional survival, and predicted survival gains if there were favourable shifts in the distribution of prognostic factors aligned with the WHO Global Breast Cancer Initiative (GBCI).

findingsBetween Sept 8, 2014, and Dec 31, 2017, 2313 women were recruited and followed up to Jan 1, 2022, and for a further year in South Africa. We excluded 87 women without breast cancer, 14 women from small racial groups (eight White and six Asian women in South Africa), 57 women with previous treatment or possible recurrences, and two women without follow-up data. The remaining 2153 (93%) women were categorised by country and race, as follows: three groups in Namibia (60 White women, 50 mixed race women, and 367 Black women), two in South Africa (37 mixed race women and 638 Black women), and one group of Black women in each of Uganda (419 women), Zambia (198 women), and Nigeria (384 women). During follow-up to at most 7 years, 1323 (61%) of 2153 women died, 672 (31%) were alive at administrative censoring, and 158 (7%) were lost to follow-up, giving crude survival at 3 years, 5 years, and 7 years of 51%, 40%, and 33%, respectively. Large between-country variations in 5-year age-standardised net survival were observed: 35-42% in Zambia and Nigeria; 52-58% in Black women in Uganda, South Africa, and Namibia; and over 83% in non-Black Namibian women. The annual probability of death (1-year conditional net survival, censored before the COVID-19 pandemic) declined generally from 2-3 years after diagnosis, but remained at 8-21% for Black women in Namibia, Uganda, and Nigeria during the fifth year after diagnosis. Reaching the GBCI 60% stage I or II target and accessing treatment would lead to an approximate reduction in deaths by a third among Black women in Namibia, Nigeria, South Africa, Uganda, and Zambia.

interpretationSurvival after breast cancer is poor in several sub-Saharan African countries, with a substantial risk of death even among women who have survived beyond 3 years after diagnosis. Understanding and preventing deaths among longer-term breast cancer survivors requires further research.

fundingNational Cancer Institute, Susan G Komen, and International Agency for Research on Cancer. TRANSLATIONS: For the Yoruba, Hausa, Igbo, Luganda and French translations of the abstract see Supplementary Materials section.

Indexed as

Breast NeoplasmsAdultAfrica South of the SaharaAgedFemaleFollow-Up StudiesHumansMiddle AgedProspective StudiesYoung Adult

Identifiers

PMID40975077
PMCPMC12446903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.